

RECOMBITEK® 4 Lepto Combos:

Comprehensive leptospirosis protection in its purest form.¹

Leptospirosis is serious.

Leptospirosis, caused by the spirochete bacteria *Leptospira*, is a zoonotic disease that occurs worldwide in domestic animals, wildlife and humans. The disease is similar in all animals and humans and may include fever, jaundice, kidney failure, abortion, and death. *Leptospira* bacteria are shed in urine and survive for months in standing water, lakes and streams.^{2,3} Therefore, prevention of shedding through vaccination may reduce the potential for further contamination of the local environment.

Protection against disease and shedding.

The RECOMBITEK family of vaccines offers a full line of modified-live, recombinant or nonadjuvanted killed vaccines for safe, potent protection. Now you have more options of targeted, pure technology your patients need and the peace of mind you deserve.

Canine Core Vaccines

RECOMBITEK Distemper – The ONLY recombinant distemper vaccine.

- Uses no live CDV — no reversion to virulence, no risk of shedding, no post-vaccinal distemper encephalitis
- In a study it protected in the presence of maternal antibodies⁴

RECOMBITEK Canine Parvo – Protection that helps close the window of vulnerability.

- Helps protect against subtypes CPV-2, CPV-2a, CPV-2b and CPV-2c^{5,6}
- In a study, efficacy confirmed in presence of maternal antibodies⁷
- High-titer, low-passage profile⁸

Leptospirosis Vaccine

RECOMBITEK 4 Lepto – Nonadjuvanted proven protection against the 4 most prevalent serovars of leptospirosis in dogs.

- The only vaccine that prevents leptospirosis caused by *Leptospira canicola*, *L. grippityphosa*, *L. icterohaemorrhagiae*, and aids in the prevention of *L. pomona*
- The only bacterin to provide a 15-month duration of immunity against *L. grippityphosa*
- Prevents your patients from shedding bacteria into the environment after exposure[†]
- Now available in a DAPP combination

[†] Prevention against leptospirosis and leptospiuria caused by *L. canicola*, *L. grippityphosa* and *L. icterohaemorrhagiae* and aids in the prevention against leptospirosis and leptospiuria caused by *L. pomona*.

Because of this...	You and your patients benefit this way...
Recombinant canarypox-vectored technology for RECOMBITEK Distemper	Safe and potent distemper protection with no reversion to virulence, no risk of shedding and no post-vaccinal distemper encephalitis.
A convenient combination: 4 Lepto/DAPP	Flexibility to fit any protocol
Safe for puppies as young as 9 weeks of age	Early protection
Nonadjuvanted, low protein formulation	Pure, proven protection

L. grippityphosa 15-month DOI

Twenty-two 9-week-old specific pathogen-free puppies were vaccinated subcutaneously, twice, 21 days apart, with a 1 mL dose of the efficacy vaccine. 470 days after the second vaccination, 20 vaccinated dogs and 22 control dogs (vaccinated with a placebo) were administered a dog virulent *Leptospira grippityphosa* challenge (RM52 isolate).⁹

100% of vaccinates were protected from leptospirosis despite most vaccinates being commingled with control dogs actively shedding spirochetes in their urine.

76.2% of the placebo control dogs developed leptospirosis.

Leptospirosis by Group

Group	Positive	Negative
Control Placebo*	16	5
Test Efficacy Vaccine**	0	20

*One dog did not complete the study **Two dogs did not complete the study

Canine Guarantee*

Merial is committed to supporting our canine vaccines. To this end, we will provide support in the event of a suspected adverse event (AE) or perceived lack of efficacy (LOE) associated with one of our vaccines.

Leptospirosis:

If a dog is found to be positive** for leptospirosis after being fully vaccinated for the corresponding serovar (receiving a full course of initial vaccines plus annual boosters as required) Merial will support diagnosis and treatment up to a maximum of \$2,500. Dogs that did not complete a full course of vaccines, or test inconclusive, will qualify for support (amount to be determined on a case-by-case basis) depending on the vaccination history of the dog.

**positive as determined by the criteria outlined in the Terms and Conditions of the Merial Pet Vaccines Customer Satisfaction Guarantee. Visit VaccinateYourPet.net for more details.

Canine Combinations:

Merial has multiple types of support for the antigens in our core vaccines (C3, C4, C6, C8 combos). In the event of a suspected lack of efficacy or adverse event, please contact our VTS group and they will assist you in determining the appropriate support.



To learn more about RECOMBITEK vaccines and how they can benefit your patients, contact your Merial Sales Representative or your Merial Distributor Representative or Call Merial Customer Care: 1-888-Merial-1 or Visit Merialconnect.comSM

***Ask your Merial Representative about our Satisfaction Guarantee on RECOMBITEK.**



¹ Nobivac: A portfolio of advanced vaccines for the well-being of canine family members [brochure]. Summit, NJ: Merck Animal Health; 2013, MAH-VC-851.

² Leptospirosis Risk in Outdoor Activities. Centers for Disease Control and Prevention website. <http://www.cdc.gov/features/leptospirosis/>. Updated July 15, 2014. Accessed March 4, 2016.

³ Greene CE, Sykes JE, et al. Leptospirosis. In: Greene CE, ed. *Infectious Diseases of the Dog and Cat*. 4th ed. St. Louis, MO: Elsevier Saunders; 2012:431-447.

⁴ Pardo MC, et al. Immunization of puppies in the presence of maternally derived antibodies against canine distemper virus. *J Comp Path*. 2007;137:S72-S75.

⁵ Welborn LV, DeVries JG, et al. Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force: 2011 AAHA Canine Vaccine Guidelines, revised. Available at: <https://www.aahanet.org/publicdocuments/caninevaccineguidelines.pdf>. Accessed November 11, 2014.

⁶ Brunet S, Toulemonde C, Cariou C, et al. Efficacy of vaccination with a canine parvovirus type 2 against a virulent challenge with CPV type 2c (Glu426). Paper presented at: International Parvovirus Meeting 2007; Bari (Italy), September 27-28, 2007.

⁷ Carlson J, Mackowiak M. Evaluation of the ability of ParvoXL vaccine to actively immunize dogs in the face of maternal immunity to canine parvovirus. Merial Research Report. 1995;CPVXL 95/005.

⁸ Greene CE, Schultz RD. Immunoprophylaxis. In: Greene CE, ed. *Infectious Diseases of the Dog and Cat*. 4th ed. St. Louis, MO: Elsevier Saunders; 2012:1163-1205.

⁹ RECOMBITEK C8 Product Label.



®RECOMBITEK is a registered trademark, and SMMerialconnect.com is a service mark, of Merial. ©2016 Merial, Inc., Duluth, GA. All rights reserved. REC16LEPTOCODTLR (03/16).

